Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8823907 | 1.00 | CTSK (0.58) | CTSKMMP3CAPN1CTSSCTSL | |
| SCHEMBL8823892 | 0.89 | CTSK (0.69) | CTSKCAPN1CTSSCTSLCTSB | |
| SCHEMBL7764593 | 0.88 | CTSL (0.65) | CTSKCAPN1CTSSCTSLCTSB | |
| SCHEMBL7315453 | 0.86 | CAPN1 (0.70) | CTSKCAPN1CTSSCTSLCTSB | |
| SCHEMBL7315481 | 0.86 | CAPN1 (0.70) | CTSKCAPN1CTSSCTSLCTSB | |
| SCHEMBL30065121 | 0.85 | CTSK (0.58) | CTSKMMP3CAPN1CTSSCTSL | |
| SCHEMBL8823953 | 0.85 | CTSK (0.54) | CTSKCAPN1CTSSCTSLCTSB | |
| SCHEMBL20173868 | 0.85 | CTSL (0.69) | CTSKMMP3CAPN1CTSSCTSL | |
| SCHEMBL8823929 | 0.84 | CTSK (0.67) | CTSKCAPN1CTSSCTSLCTSB | |
| SCHEMBL8823925 | 0.84 | CTSK (0.67) | CTSKCAPN1CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997049668-A1 | INHIBITIORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | claimed |
| WO-1997049668-A1 | INHIBITIORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |